申请人:Ono Pharmaceutical Co., Ltd.
                            
                            
                                公开号:EP2055705A1
                            
                            
                                公开(公告)日:2009-05-06
                            
                            
A compound represented by general formula (I):
a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.
                            通式 (I) 所代表的化合物:
其盐、其溶液或其原药,其中所有符号如说明书中所定义,具有拮抗 CXCR4 的活性,因此可用作 CXCR4 介导的疾病的预防和/或治疗剂,例如炎症性和免疫性疾病(如类风湿性关节炎、关节炎、视网膜病变、黄斑变性、肺纤维化、移植器官排斥等)。例如,类风湿性关节炎、关节炎、视网膜病变、黄斑变性、肺纤维化、移植器官排斥等)、过敏性疾病、感染(例如,人类免疫缺陷病毒感染、获得性免疫缺陷综合征等)、精神神经性疾病、脑部疾病、心血管疾病、代谢性疾病、癌症疾病(例如,癌症、癌症转移等)、癌症疾病或感染的预防和/或治疗剂或再生治疗剂。